On January 5, 2018 Spectrum Pharmaceuticals presented Presentation materials dated January 8, 2018 (Presentation, Spectrum Pharmaceuticals, JAN 5, 2018, View Source [SID1234523078]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 5, 2018 Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA) constructs, reported that the company is scheduled to present at the 10th Annual Biotech Showcase conference held January 8-10, 2018 in San Francisco (Press release, Exicure, JAN 5, 2018, View Source;p=RssLanding&cat=news&id=2325180 [SID1234523073]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. David Giljohann, Chief Executive Officer of Exicure, will present a company overview on Tuesday, January 9th at 10:15 a.m. Pacific Time at the Hilton Union Square in San Francisco.

A live webcast of the presentation will be available on the Events & Presentations section of Exicure’s website and will also be archived following the presentation.

On January 5, 2018 AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), reported that it will present at Biotech Showcase, January 8-10, 2018 at the Hilton San Francisco Union Square (Press release, BioTime, JAN 5, 2018, View Source;p=RssLanding&cat=news&id=2325217 [SID1234522928]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Michael D. West, Ph.D., Chief Executive Officer, will present at the conference as follows:

Date: Tuesday, January 9
Time: 2:30 PM PST
Track: Yosemite-B (Ballroom Level)
Venue: Hilton San Francisco Union Square, 333 O’Farrell Street

According to the event organizers, Biotech Showcase features more than 3,500 decision makers from 2,100 life sciences companies in a variety of plenary sessions, fireside chats, and panels. This year’s event is expected to draw over 900 investors from 50-plus countries, in anticipation of 400-plus public and private company presentations.

A copy of Dr. West’s presentation will be available on the AgeX website.

On January 5, 2018 NantWorks, the parent organization of NantHealth (NASDAQ: NH) and NantKwest (NASDAQ: NK) reported that Dr. Patrick Soon-Shiong (Chairman, CEO, and Founder) will present the current status of these companies and the overall ecosystem of NantWorks (Press release, NantKwest, JAN 5, 2018, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2325231 [SID1234522931]). Specific details will be presented regarding the current status of GPS CancerTM, including FDA filings and seminal patents issued covering tumor-normal analysis of DNA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, details will be presented regarding the record 25 letters of authorization covering 12 novel biological molecules tested across 20 tumor types within the NantWorks ecosystem of companies, of which 15 letters of authorization were received in 2017 for natural killer cells in combination with adenovirus, yeast, super agonist IL-15 and checkpoint inhibitors. The preliminary results of the first in human and safety studies of the NANT Cancer Vaccine will be released.

Presentation Time:

Time: January 9, 2018 at 5:00pm Pacific Time.
Location: 36th Annual J.P. Morgan Healthcare Conference – Elizabethan A/B Breakout: Sussex Room
Both the presentation and question and answer session that follows at 5:00pm will be webcast live at the below links and available for replay at both NantHealth and NantKwest.

NantWorks Presents at the 36th Annual J.P. Morgan Healthcare Conference
NantWorksQ & A Session at the 36th Annual J.P. Morgan Healthcare Conference

On January 4, 2018 Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, reported that Randal J. Kirk, Chairman and Chief Executive Officer will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10th at 9:30 a.m. Pacific Time (Press release, Intrexon, JAN 4, 2018, View Source [SID1234522882]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors section of Intrexon’s website at View Source Replay of the webcast will be available for 30 days following the event.